CO2021017414A2 - Anticuerpos anti-angpt2 - Google Patents
Anticuerpos anti-angpt2Info
- Publication number
- CO2021017414A2 CO2021017414A2 CONC2021/0017414A CO2021017414A CO2021017414A2 CO 2021017414 A2 CO2021017414 A2 CO 2021017414A2 CO 2021017414 A CO2021017414 A CO 2021017414A CO 2021017414 A2 CO2021017414 A2 CO 2021017414A2
- Authority
- CO
- Colombia
- Prior art keywords
- angpt2
- angpt2 antibodies
- antibodies
- angiopoietin
- diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a anticuerpos neutralizantes anti-angiopoyetina 2 (ANGPT2) novedosos para métodos de tratamiento y diagnóstico y una composición en la que se usan.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962867253P | 2019-06-27 | 2019-06-27 | |
US202063013022P | 2020-04-21 | 2020-04-21 | |
PCT/US2020/039477 WO2020264065A1 (en) | 2019-06-27 | 2020-06-25 | Anti-angpt2 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021017414A2 true CO2021017414A2 (es) | 2022-01-17 |
Family
ID=71662321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0017414A CO2021017414A2 (es) | 2019-06-27 | 2021-12-17 | Anticuerpos anti-angpt2 |
Country Status (19)
Country | Link |
---|---|
US (2) | US11396539B2 (es) |
EP (1) | EP3990489A1 (es) |
JP (1) | JP2022538062A (es) |
KR (1) | KR20220028032A (es) |
CN (1) | CN114080396B (es) |
AU (1) | AU2020308569A1 (es) |
BR (1) | BR112021024176A2 (es) |
CA (1) | CA3140071A1 (es) |
CL (1) | CL2021003367A1 (es) |
CO (1) | CO2021017414A2 (es) |
CR (1) | CR20210683A (es) |
EC (1) | ECSP22004680A (es) |
IL (1) | IL289160A (es) |
JO (1) | JOP20210339A1 (es) |
MA (1) | MA56394A (es) |
MX (1) | MX2021015743A (es) |
PE (1) | PE20220809A1 (es) |
TW (1) | TW202115112A (es) |
WO (1) | WO2020264065A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202115112A (zh) * | 2019-06-27 | 2021-04-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE266710C (es) | ||||
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4419446A (en) | 1980-12-31 | 1983-12-06 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant DNA process utilizing a papilloma virus DNA as a vector |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4434173A (en) | 1982-08-23 | 1984-02-28 | Pfizer Inc. | Bis-esters of 4,5-di(hydroxymethyl)-2-oxo-1,3-dioxole as antibacterial agents |
US4601978A (en) | 1982-11-24 | 1986-07-22 | The Regents Of The University Of California | Mammalian metallothionein promoter system |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
EP0435911B1 (en) | 1988-09-23 | 1996-03-13 | Cetus Oncology Corporation | Cell culture medium for enhanced cell growth, culture longevity and product expression |
FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
US6455035B1 (en) * | 1999-03-26 | 2002-09-24 | Regeneron Pharmaceuticals, Inc. | Angiopoietins and methods of use thereof |
US7973140B2 (en) * | 2004-12-21 | 2011-07-05 | Medimmune Limited | Antibodies directed to angiopoietin-2 and uses thereof |
US8133979B2 (en) * | 2008-12-16 | 2012-03-13 | Hoffmann-La Roche Inc. | Antibodies against human angiopoietin 2 |
JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
US20110227286A1 (en) * | 2010-03-18 | 2011-09-22 | Davies Janet L | Board Game and Method of Playing the Same |
US9575073B2 (en) * | 2011-10-10 | 2017-02-21 | Rutgers, The State University Of New Jersey | Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma |
US20150044227A1 (en) | 2012-03-08 | 2015-02-12 | Medimmune, Llc | Methods of treatment with angiopoietin-2 antibodies |
EP2832746B1 (en) | 2013-07-29 | 2018-07-18 | Samsung Electronics Co., Ltd | Anti-Ang2 antibody |
WO2015091655A1 (en) | 2013-12-20 | 2015-06-25 | F. Hoffmann-La Roche Ag | Combination therapy with an anti-ang2 antibody and a cd40 agonist |
AR100270A1 (es) * | 2014-05-19 | 2016-09-21 | Lilly Co Eli | Anticuerpos ang2 |
BR112017010498A2 (pt) * | 2014-11-19 | 2017-12-26 | Axon Neuroscience Se | anticorpos tau humanizados em doença de alzheimer |
US11485775B2 (en) * | 2016-10-21 | 2022-11-01 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
US10759870B2 (en) * | 2017-09-29 | 2020-09-01 | Chugai Seiyaku Kabushiki Kaisha | Multispecific antigen-binding molecules having blood coagulation factor VIII (FVIII) cofactor function-substituting activity and pharmaceutical formulations containing such a molecule as an active ingredient |
TW202115112A (zh) * | 2019-06-27 | 2021-04-16 | 德商百靈佳殷格翰國際股份有限公司 | 抗-angpt2抗體 |
-
2020
- 2020-06-24 TW TW109121573A patent/TW202115112A/zh unknown
- 2020-06-25 JP JP2021576151A patent/JP2022538062A/ja active Pending
- 2020-06-25 KR KR1020227003085A patent/KR20220028032A/ko unknown
- 2020-06-25 MA MA056394A patent/MA56394A/fr unknown
- 2020-06-25 MX MX2021015743A patent/MX2021015743A/es unknown
- 2020-06-25 JO JOP/2021/0339A patent/JOP20210339A1/ar unknown
- 2020-06-25 PE PE2021002220A patent/PE20220809A1/es unknown
- 2020-06-25 CR CR20210683A patent/CR20210683A/es unknown
- 2020-06-25 AU AU2020308569A patent/AU2020308569A1/en active Pending
- 2020-06-25 WO PCT/US2020/039477 patent/WO2020264065A1/en active Application Filing
- 2020-06-25 BR BR112021024176A patent/BR112021024176A2/pt unknown
- 2020-06-25 CN CN202080047312.1A patent/CN114080396B/zh active Active
- 2020-06-25 EP EP20742550.5A patent/EP3990489A1/en active Pending
- 2020-06-25 CA CA3140071A patent/CA3140071A1/en active Pending
- 2020-06-25 US US16/911,419 patent/US11396539B2/en active Active
-
2021
- 2021-12-16 CL CL2021003367A patent/CL2021003367A1/es unknown
- 2021-12-17 CO CONC2021/0017414A patent/CO2021017414A2/es unknown
- 2021-12-20 IL IL289160A patent/IL289160A/en unknown
-
2022
- 2022-01-19 EC ECSENADI20224680A patent/ECSP22004680A/es unknown
- 2022-06-17 US US17/842,904 patent/US20220363743A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2020308569A1 (en) | 2021-12-02 |
US20200407435A1 (en) | 2020-12-31 |
CN114080396B (zh) | 2024-05-17 |
PE20220809A1 (es) | 2022-05-20 |
CN114080396A (zh) | 2022-02-22 |
US11396539B2 (en) | 2022-07-26 |
EP3990489A1 (en) | 2022-05-04 |
WO2020264065A1 (en) | 2020-12-30 |
BR112021024176A2 (pt) | 2022-03-22 |
TW202115112A (zh) | 2021-04-16 |
JP2022538062A (ja) | 2022-08-31 |
JOP20210339A1 (ar) | 2023-01-30 |
CR20210683A (es) | 2022-02-23 |
CL2021003367A1 (es) | 2022-10-07 |
ECSP22004680A (es) | 2022-02-25 |
KR20220028032A (ko) | 2022-03-08 |
IL289160A (en) | 2022-02-01 |
MA56394A (fr) | 2022-05-04 |
CA3140071A1 (en) | 2020-12-30 |
MX2021015743A (es) | 2022-01-27 |
US20220363743A1 (en) | 2022-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
CO2018004743A2 (es) | Proteínas de unión al antígeno anti-tigit y métodos para usarlas | |
CL2018001971A1 (es) | Ror1 composiciones de anticuerpos y métodos relacionados | |
CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
CL2021000516A1 (es) | Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) | |
GT201200318A (es) | Anticuerpos hacia gdf8 humano | |
BR112021019334A2 (pt) | Anticorpos de cadeia pesada que se ligam ao psma | |
BR112019012796A2 (pt) | proteínas de ligação ao antígeno antineuropilina e métodos de uso das mesmas | |
CL2021000909A1 (es) | Anticuerpos estabilizadores de trem2 | |
BR112021024956A2 (pt) | Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3 | |
BR112016017764A2 (pt) | anticorpo antidengue de amplo espectro | |
BR112022003956A2 (pt) | Anticorpos anti-cd73 | |
CO2021011944A2 (es) | Anticuerpos de cd33 y métodos para usar los mismos para tratar el cáncer | |
BR112022003740A2 (pt) | Anticorpos anti-cd96 e métodos de uso dos mesmos | |
BR112019010128A2 (pt) | proteínas de ligação a antígeno anti-gitr e métodos de uso das mesmas | |
AR114129A1 (es) | ANTICUERPOS TERAPÉUTICOS DIRIGIDOS CONTRA sPLA2-GIB Y SUS USOS | |
ZA201907371B (en) | Methods and compositions for treating allergic ocular diseases | |
UY36262A (es) | Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso | |
MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
CO2023017156A2 (es) | Anticuerpos anti-sirp-alfa | |
EA201992317A1 (ru) | Композиции и способы для диагностики рака легких | |
ECSP22004680A (es) | Anticuerpos anti-angpt2 | |
CO2023015915A2 (es) | Anticuerpos anti-ccr8 | |
BR112022001199A2 (pt) | Imunoterapia para poliomavírus |